THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN

Aim. To evaluate the diagnostic value of heart-type fatty acid-binding protein (H-FABP) introduction to standard cardiac biomarkers in diagnostics of myocardial infarction (MI) early after clinical symptoms onset. Material and methods. Patients aged 18 years and older admitted to the hospital with a...

Full description

Bibliographic Details
Main Authors: O. V. Baturina, S. R. Gilyarevsky, I. M. Kuzmina, M. A. Godkov, E. V. Klychnikova
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/430
id doaj-d202ddb461cf4e889ad5abac1870d19c
record_format Article
spelling doaj-d202ddb461cf4e889ad5abac1870d19c2021-09-03T13:15:16ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-12-018340541410.20996/1819-6446-2012-8-3-405-414430THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEINO. V. Baturina0S. R. Gilyarevsky1I. M. Kuzmina2M. A. Godkov3E. V. Klychnikova4Research Institute of Emergency Medicine named after N.V. SklifosovskyResearch Institute of Emergency Medicine named after N.V. SklifosovskyResearch Institute of Emergency Medicine named after N.V. SklifosovskyResearch Institute of Emergency Medicine named after N.V. SklifosovskyResearch Institute of Emergency Medicine named after N.V. SklifosovskyAim. To evaluate the diagnostic value of heart-type fatty acid-binding protein (H-FABP) introduction to standard cardiac biomarkers in diagnostics of myocardial infarction (MI) early after clinical symptoms onset. Material and methods. Patients aged 18 years and older admitted to the hospital with acute coronary syndrome (ACS) during first 6 hours after ACS symptoms onset were enrolled into the study. At hospitalization level of biomarkers of myocardial damage (creatine phosphokinase-MB fraction - CPK-MB, troponin T) and qualitative tests on FABP were assessed in all patients. Serum troponin T concentration measured in 12 hours after the hospitalization was used to confirm diagnosis of MI. Moreover , diagnosis of MI was verified by echocardiography with the assessment of local reduction in myocardial contractility. Results. 101 patients were included into the study (27% female; aged 59.9±12.4). At the moment of hospitalization 71 (70%) patients were diagnosed with ACS with ST-segment elevation, and 30 (30%) patients - ACS without ST-segment elevation. In total, period between clinical symptoms onset and hospitalization was 3.6±1.4 hours. Analysis of diagnostic value of tests during the first 6 hours after ACS symptoms onset showed higher sensitivity of H-FABP in comparison with troponin T and CPK-MB (72.5, 56.2 and 49.5%, respectively). Specificity of these tests during the first 6 hours after onset of clinical signs of ACS was 90, 100 и 90%, respectively.  Sensitivity and specificity were 87.7 and 100.0%, respectively , when H-FABP , troponin T and CPK-MB were used in combination as a “block test” in patients hospitalized during the first 6 hours after ACS symptoms onset. Sensitivity and specificity were 74.3 и 100.0%, respectively , when “block test” was used in patients hospitalized during the first 3 hours after ACS symptoms onset; between 3 and 6 hours after ACS symptoms onset sensitivity and specificity of tests reached 100%. Conclusion. “Block test” with H-FABP , troponin T and CPK-MB early after ACS symptoms onset is more sensitive in comparison with separate use of the tests.https://www.rpcardio.com/jour/article/view/430heart-type fatty acid-binding proteinacute coronary syndrome“block” test
collection DOAJ
language English
format Article
sources DOAJ
author O. V. Baturina
S. R. Gilyarevsky
I. M. Kuzmina
M. A. Godkov
E. V. Klychnikova
spellingShingle O. V. Baturina
S. R. Gilyarevsky
I. M. Kuzmina
M. A. Godkov
E. V. Klychnikova
THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
Racionalʹnaâ Farmakoterapiâ v Kardiologii
heart-type fatty acid-binding protein
acute coronary syndrome
“block” test
author_facet O. V. Baturina
S. R. Gilyarevsky
I. M. Kuzmina
M. A. Godkov
E. V. Klychnikova
author_sort O. V. Baturina
title THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
title_short THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
title_full THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
title_fullStr THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
title_full_unstemmed THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN
title_sort efficacy of combined biomarker tests in early diagnostics of acute myocardial infarction after clinical symptoms onset: role of heart-type fatty acid-binding protein
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-12-01
description Aim. To evaluate the diagnostic value of heart-type fatty acid-binding protein (H-FABP) introduction to standard cardiac biomarkers in diagnostics of myocardial infarction (MI) early after clinical symptoms onset. Material and methods. Patients aged 18 years and older admitted to the hospital with acute coronary syndrome (ACS) during first 6 hours after ACS symptoms onset were enrolled into the study. At hospitalization level of biomarkers of myocardial damage (creatine phosphokinase-MB fraction - CPK-MB, troponin T) and qualitative tests on FABP were assessed in all patients. Serum troponin T concentration measured in 12 hours after the hospitalization was used to confirm diagnosis of MI. Moreover , diagnosis of MI was verified by echocardiography with the assessment of local reduction in myocardial contractility. Results. 101 patients were included into the study (27% female; aged 59.9±12.4). At the moment of hospitalization 71 (70%) patients were diagnosed with ACS with ST-segment elevation, and 30 (30%) patients - ACS without ST-segment elevation. In total, period between clinical symptoms onset and hospitalization was 3.6±1.4 hours. Analysis of diagnostic value of tests during the first 6 hours after ACS symptoms onset showed higher sensitivity of H-FABP in comparison with troponin T and CPK-MB (72.5, 56.2 and 49.5%, respectively). Specificity of these tests during the first 6 hours after onset of clinical signs of ACS was 90, 100 и 90%, respectively.  Sensitivity and specificity were 87.7 and 100.0%, respectively , when H-FABP , troponin T and CPK-MB were used in combination as a “block test” in patients hospitalized during the first 6 hours after ACS symptoms onset. Sensitivity and specificity were 74.3 и 100.0%, respectively , when “block test” was used in patients hospitalized during the first 3 hours after ACS symptoms onset; between 3 and 6 hours after ACS symptoms onset sensitivity and specificity of tests reached 100%. Conclusion. “Block test” with H-FABP , troponin T and CPK-MB early after ACS symptoms onset is more sensitive in comparison with separate use of the tests.
topic heart-type fatty acid-binding protein
acute coronary syndrome
“block” test
url https://www.rpcardio.com/jour/article/view/430
work_keys_str_mv AT ovbaturina theefficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT srgilyarevsky theefficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT imkuzmina theefficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT magodkov theefficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT evklychnikova theefficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT ovbaturina efficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT srgilyarevsky efficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT imkuzmina efficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT magodkov efficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
AT evklychnikova efficacyofcombinedbiomarkertestsinearlydiagnosticsofacutemyocardialinfarctionafterclinicalsymptomsonsetroleofhearttypefattyacidbindingprotein
_version_ 1717816970317922304